An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer.

Trial Profile

An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Sponsors Merck KGaA
  • Most Recent Events

    • 09 Nov 2014 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 22 Feb 2013 Planned end date changed from 1 Jul 2014 to 1 Apr 2017 as reported by ClinicalTrials.gov.
    • 25 Feb 2011 New source identified and integrated (Clinical Trials Registry - India, CTRI2010-091-000161).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top